Minireviews
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Meta-Anal. Apr 18, 2023; 11(4): 92-101
Published online Apr 18, 2023. doi: 10.13105/wjma.v11.i4.92
Lipocalin-2 as a biomarker for diabetic nephropathy
Kiran Dahiya, Praveen Prashant, Rakesh Dhankhar, Kumud Dhankhar, Sushil Kumar, Sonia Vashist
Kiran Dahiya, Praveen Prashant, Department of Biochemistry, Pt BD Sharma Post Graduate Institute of Medical Sciences, Rohtak 124001, Haryana, India
Rakesh Dhankhar, Department of Radiation Oncology, Pt BD Sharma Post Graduate Institute of Medical Sciences, Rohtak 124001, India
Kumud Dhankhar, Phase III, JSS Medical College, Mysuru 570015, Karnataka, India
Sushil Kumar, Civil Hospital, Jhajjar 124103, Haryana, India
Sonia Vashist, Department of Dermatology, Dr Sonia’s Dermatology Clinic, Rewari 123401, Haryana, India
Author contributions: Dahiya K contributed to concept designing, content writing, and manuscript formatting; Prashant P explored the resources, prepared the manuscript, formatted and compiled the content, and coordinated the report; Dhankhar R contributed to manuscript preparation and manuscript proofreading and formatting; Dhankhar K contributed to manuscript writing, designing, and proofreading; Kumar S contributed to manuscript preparation and content compilation; Vashist S contributed to manuscript writing, content compilation, and proofreading.
Conflict-of-interest statement: All the authors report have no conflicts of interest to disclose for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial(CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Kiran Dahiya, MBBS, MD, Doctor, Professor, Department of Biochemistry, Pt BD Sharma Post Graduate Institute of Medical Sciences, Pt BD Sharma University of Health Sciences, Rohtak 124001, Haryana, India. kirandahiya_2002@yahoo.com
Received: December 23, 2022
Peer-review started: December 23, 2022
First decision: February 21, 2023
Revised: March 11, 2023
Accepted: March 29, 2023
Article in press: March 29, 2023
Published online: April 18, 2023
Processing time: 111 Days and 22.4 Hours
Core Tip

Core Tip: Diabetic nephropathy (DN) is a chronic complication of diabetes. The mainstay markers for kidney injury are a gradual decrease in glomerular filtration rate and microalbuminuria. Microalbuminuria appears late in DN; thus, new biomarkers are required. Different researchers highlighted the role of lipocalin-2 (NGAL) in the early detection of nephropathy before the appearance of microalbumin in urine. In this review, we briefly describe the role of NGAL in various diseases and cancers and detail its role as an early biomarker in DN.